News & Updates

Adding cabozantinib to nivolumab and ipilimumab as first-line therapy, compared with placebo, results in prolonged progression-free survival (PFS) among untreated patients with advanced renal cell carcinoma (RCC), with no new safety signals seen, as shown by the results of the phase III COSMIC-313 study.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes and cancer results in significantly reduced mortality and hospitalizations relative to treatment with metformin, a study has shown.

A study from the US finds that compared with afternoon infusions, morning infusions of immune checkpoint inhibitors (ICI) confer a modest but clinically meaningful overall survival (OS) benefit to patients with non-small-cell lung cancer (NSCLC).